symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
ANTX,14.54,0,60107,431928148,7.138542,4.87-19.25,-0.35,"AN2 Therapeutics, Inc.",USD,0001880438,,037326105,NASDAQ Global Select,NASDAQ,Biotechnology,https://www.an2therapeutics.com,"AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.",Mr. Eric E. Easom,Healthcare,US,35,650-331-9090,1800 El Camino Real,Menlo Park,CA,94027,0.0411383,12.6111,https://financialmodelingprep.com/image-stock/ANTX.png,2022-03-25,False,False,True,False,False
